Actively Recruiting
Phase III Study of VRT106 Injection Given Intravenously to Adults With Recurrent or Progressive Glioblastoma to Assess Safety and Effectiveness
Led by Guangzhou Virotech Pharmaceutical Co., Ltd. · Updated on 2026-01-02
42
Participants Needed
11
Research Sites
25 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of VRT106 in adults with recurrent or progressive glioblastoma. This open-label, single-arm Phase III clinical trial includes patients aged 18 to 70 years. The study aims to find the best dose of VRT106 and further assess its impact on this brain cancer condition. The trial has two parts Phase I involves gradually increasing doses of VRT106 given intravenously to find a safe and tolerable dose. Phase II uses this recommended dose to further study VRT106s effects and safety in participants. Treatment is given through intravenous infusion, and the study carefully monitors patients throughout these phases. Participants will undergo regular assessments including safety evaluations, monitoring of overall survival, response to treatment, and tracking of the VRT106 virus in the body. The study lasts about two years, during which researchers will collect data to understand how participants respond to the treatment and ensure close safety monitoring.
CONDITIONS
Brief Title
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Research Team
C
Chengcheng Guo
K
Ke Sai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
